Sequella Home Page

Quick Facts

Four percent of MDR-TB cases in the U.S. met the criteria for XDR-TB

Press Releases and Articles

Latest News

Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis

Sequella, Inc. Selected to Present at Cavendish Global Health Impact Forum

Sequella Presents Four Scientific Posters in September at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC

Sequella CEO Delivers Keynote Address at McGill International TB Center in Montreal Canada

Lead Antitubercular Drug Candidate SQ109 Begins New Multi-Arm, Multi-Stage (MAMS) Clinical Trial in Tanzania and South Africa




For further information, please contact:

Alicia Moran
AM Media and Marketing

Telephone: 410-991-7027

Carol Nacy, CEO

Sequella, Inc.
Telephone: 301-762-7776